Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39
Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial
New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years
Two Phase II Trials Display Ramucirumab Potential Efficacy
Gene Variant Associated With 44 Percent Cancer Risk Reduction
Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant
HCT Survivors More Likely To Show Heart Disease Risk Factors
PV-10 Produces 51 Percent Response Rate in Phase II Trial
Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
Three Studies Test Oncotype DX In Breast and Colon Cancers
NCI-Approved CTEP Trials For the Month of October
FDA Approves Abraxane And Alimta for NSCLC
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Leading a Comprehensive Cancer Center—one job or two?
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- “This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation
- Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week - Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures
